MAP Pharmaceuticals has appointed W. James O'Shea, a former President and COO of Sepracor, to its board of directors. During eight years at Sepracor, O'Shea held a number of positions in operations and commercialization and had previously worked for Zeneca Pharmaceuticals, including as Senior VP of Sales and Marketing and Medical Affairs. MAP is preparing for the … [Read more...] about MAP adds James O’Shea to board of directors
People
VaryDose appoints Philippe Rogueda as CTO
UK dry powder dispensing company VaryDose has announced the appointment of Philippe Rogueda as its Chief Technology Officer. According to the company, "Philippe brings with him many years’ experience and expertise in the powder handling and pharmaceutical formulation industry. Philippe is an industry renowned product development specialist with extensive experience of … [Read more...] about VaryDose appoints Philippe Rogueda as CTO
MannKind and former regulatory affairs director resolve legal issues
According to MannKind Corporation, it has completely resolved arbitration initiated by a lawsuit filed by its former Senior Director - GCP - Regulatory Affairs, John Arditi, in 2010. Arditi, who had been responsible for MannKind's GCP compliance audit program, claimed in the lawsuit that he was terminated in retaliation "for his diligence and insistence on quality … [Read more...] about MannKind and former regulatory affairs director resolve legal issues
Powder Flow 2011 poster prize awarded to Hanne Kinnunen
The prize for the best poster presented at PowderFlow 2011 was awarded to Hanne Kinnunen, a PhD student in the Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology at the University of Bath, for her poster titled, "The impact of loaded drug dose and the surface roughness of the coarse lactose carrier to the fluidisation … [Read more...] about Powder Flow 2011 poster prize awarded to Hanne Kinnunen
Bloomberg highlights changes in GSK respiratory drug research
Bloomberg has published an article about GSK's overhaul of its R&D organization that describes former head of the allergic inflammation discovery performance unit Roberto Solari as "one of the casualties of the company’s new approach to drug discovery." According to the article, a spokesperson for GSK confirmed that Solari, whom the author describes as "an unassuming … [Read more...] about Bloomberg highlights changes in GSK respiratory drug research
Malvern Instruments scientist wins microscopy award
The New York Microscopical Society has recognized Malvern Instruments Chief Technology Officer E. Neil Lewis with its Ernst Abbe Memorial Award for outstanding contributions to the science of microscopy. The society specifically cited Dr. Lewis's development of chemical imaging microscopy. The award was presented at the 50th Eastern Analytical Symposium & … [Read more...] about Malvern Instruments scientist wins microscopy award
James Ingebrand is new VP and General Manager at 3M DDS
James Vaughan has retired as Vice President and General Manager of 3M Drug Delivery Systems, and the company has announced the appointment of James Ingebrand to replace him. Ingebrand has been with 3M for 27 years and has held a number of positions, including Inhalation Program Manager. According to 3M, “As Vice President and General Manager, Ingebrand will assume … [Read more...] about James Ingebrand is new VP and General Manager at 3M DDS
New scientific advisory board for Prosonix
Ken Cunningham, who recently joined the board of UK pharmaceutical and particle engineering company Prosonix, will lead the company's new scientific advisory board. Joining Cunningham on Prosonix's SAB are: Peter Barnes, Professor of Thoracic Medicine and Head of Airway Disease, National Heart and Lung Institute, and Honorary Consultant Physician, Royal Brompton … [Read more...] about New scientific advisory board for Prosonix
Azelon gets financing for osteoporosis nasal spray, adds to management team
Prospect Venture Partners, Lighthouse Capital Partners, and Covington Venture Fund will provide a total of $4.5 million in Series A financing to Azelon Pharmaceuticals, formerly Zelos Therapeutics, for continued clinical development of Azelon’s ZT-034 teriparatide nasal spray for the treatment of osteoporosis. Teriparatide is a parathyroid hormone analog and is … [Read more...] about Azelon gets financing for osteoporosis nasal spray, adds to management team
Michael Yeadon appointed to Pulmatrix scientific advisory board
Inhaled pharmaceuticals developer Pulmatrix has named former Pfizer VP Michael Yeadon as an advisor to its management team and as the newest member of its scientific advisory board. Yeadon joined Pfizer in 1995 and was most recently that company's Vice President and Chief Scientific Officer of the Allergy and Respiratory Unit. He is currently an industry … [Read more...] about Michael Yeadon appointed to Pulmatrix scientific advisory board